(redirected from B-Cell Chronic Lymphocytic Leukemia)
Also found in: Wikipedia.
BCLLB-Cell Chronic Lymphocytic Leukemia
BCLLBridge City Little League (Bridge City, TX)
BCLLBenedictine Center for Lifelong Learning (Minnesota)
BCLLBritish Company Law Library (UK)
BCLLB Cell Lymphoma Line (immunology)
References in periodicals archive ?
Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.
The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects
Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies.
The United States Food and Drug Administration recently authorized Alexion's Investigational New Drug application for a clinical trial of ALXN6000 as a treatment for patients with refractory or relapsing B-cell Chronic Lymphocytic Leukemia (CLL).
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia.
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
a unit of German-based Schering AG, and is currently FDA-approved to treat a type of leukemia, B-cell chronic lymphocytic leukemia B-CLL).
24) Soluble CD44 has been found in the serum of patients with various metastasized cancers and hematologic malignancies (12) such as B-cell chronic lymphocytic leukemia, (25) acute leukemias, (26) myelodysplastic syndromes, and NHL, and in some cases was associated with a poor clinical outcome.
15 January 2010 - US-based biopharmaceutical company CytRx Corporation (NASDAQ:CYTR) said on Wednesday it plans to initiate a Phase II proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib (formerly known as INNO-406) in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).